Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

NCT04216316 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

NIH

Sponsor class

Conditions

Lung Non-Small Cell Squamous Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions

DRUG: Berzosertib
PROCEDURE: Biospecimen Collection
DRUG: Carboplatin
PROCEDURE: Computed Tomography
DRUG: Gemcitabine Hydrochloride
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)